Search bioRxiv⌕ Search

bioRxiv · 10.1101/2025.11.12.688019

Leveraging FracMinHash Containment for Genomic dN/dS

Abstract

Increasing availability of genomic data demands algorithmic approaches that can efficiently and accurately conduct downstream genomic analyses. These analyses, such as evaluating selection pressures within and across genomes, can reveal developmental and environmental pressures. One such commonly used metric to measure evolutionary pressures is based on the ratio of non-synonymous and synonomous substitution rates, dN/dS. Conventionally, the dN/dS ratio is used to infer selection pressures employing alignments to estimate total non-synonymous and synonymous substitution rates along protein-coding genes. However, this process can be time consuming and not scalable for larger datasets. Recently, a fast, approximate similarity measure, FracMinHash containment, was introduced and related to average nucleotide identity. In this work, we show how FracMinHash containment can be used to quickly estimate dN/dS enabling alignment-free estimations at a genomic level. Through simulated and real world experiments, our results indicate that employing FracMinHash containment to estimate dN/dS is scalable, enabling pairwise dN/dS estimations for 85,205 genomes within 5 hours. Furthermore, our approach is comparable to traditional dN/dS methods, representing sequences subject to positive and negative selection across various mutation rates. Moreover, we used this model to evaluate signatures of selection between Archaeal and Bacterial genomes, identifying a previously unreported metabolic island between Methanobrevibacter sp. RGIG2411 and Candidatus Saccharibacteria bacterium RGIG2249. We present, FracMinHash dN/dS, a novel alignment-free approach for estimating dN/dS at a genome level that is accurate and scalable beyond gene-level estimations while demonstrating comparability to conventional alignment-based dN/dS methods. Leveraging the alignment-free similarity estimation, FracMinHash containment, pairwise dN/dS estimations are facilitated within milliseconds, making it suitable for large-scale evolutionary analyses across diverse taxa. It supports comparative genomics, evolutionary inference, and functional interpretation across both synthetic, and complex biological datasets. Availability and implementationA version of the implementation is available at https://github.com/KoslickiLab/dnds-using-fmh.git. The reproduction of figures, data, and analysis can be found at https://github.com/KoslickiLab/dnds-using-fmh_reproducibles.git. Contactdmk333@psu.edu Supplementary informationSupplementary data are available at PLOS Computational Biology online. Author summaryUnderstanding how evolution shapes genomes helps us learn about the pressures organisms face in their environments. Scientists traditionally measure this by comparing genetic changes that alter proteins versus those that dont, a ratio that reveals whether natural selection is preserving or changing genes. However, this conventional approach requires computationally intensive sequence alignments, making it impractical for analyzing the massive genomic datasets now available. We developed a faster, alignment-free method to estimate evolutionary pressure across entire genomes. Our approach uses a computational technique called FracMinHash that compresses genomic information while preserving meaningful patterns. We tested our method on both simulated and real-world data, including over 85,000 microbial genomes, completing the analysis in just five hours whereas traditional methods would take days or weeks for the same analysis. The results were comparable to traditional methods and correctly identified genes under different types of selection. Using this approach, we discovered a previously unreported shared genetic region between an archaeal and bacterial species from the goat gut microbiome, suggesting ancient gene transfer between these distant branches of life. Our method makes large-scale evolutionary analysis practical for diverse applications, from tracking microbial strains to understanding adaptation in complex microbial communities, potentially accelerating discoveries in comparative genomics and evolutionary biology.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Rodriguez, J. S., Hera, M. R., Koslicki, D.. 2025-11-13. Leveraging FracMinHash Containment for Genomic dN/dS. https://doi.org/10.1101/2025.11.12.688019

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Heterogeneous Graph Contrastive Learning for Drug-Gene-Disease Motif Prediction

Drug repurposing and target discovery offer critical strategies for advancing therapeutic development by uncovering the potential biological pathways and novel associations among drugs, genes, and diseases. However, experimental discovery remains expensive and time-consuming, which limits the scalability of large-scale studies. In addition, existing computational approaches often struggle to effectively integrate heterogeneous biomedical data, capture the complex higher-order topological signatures of biological interactomes, and generalize to unseen entities. Here, we present HANAMI (Heterogeneous grAph coNtrastive leArning for drug-gene-disease Motif predIction), a multi-view deep graph learning framework designed to model complex interactions among drugs, genes, and diseases. HANAMI integrates diverse heterogeneous biomedical knowledge, including chemical structures, genomic sequences, and clinical phenotypes, and leverages relation-aware topology encoding, structure-aware aggregation, and contrastive learning to enable accurate motif prediction with biological context from the network. Systematic evaluation on benchmark datasets shows that HANAMI achieves up to 6% improvements over existing state-of-the-art methods in predicting drug-gene-disease motifs. The framework further demonstrates strong inductive generalization, maintaining an [~]18% performance advantage in zero-shot settings involving previously unseen entities. Beyond predictive performance, HANAMI effectively prioritizes drug-disease relationships investigated in Phase II or III trials while identifying candidate genes that suggest plausible mechanistic links. Together, HANAMI provides a computational framework for interpreting complex biomedical interactions, offering a scalable foundation to accelerate drug repurposing and therapeutic innovation.

bioinformatics↗

PTMExplorer: A Multi-Dimensional Integrative Visualization Platform for Protein Post-Translational Modification Function and Structure

Deciphering the functions of post-translational modifications (PTMs) is a critical bridge connecting large-scale modification proteomics data to mechanistic studies. However, most existing tools for visualizing PTM omics data are limited to site catalogs or single-dimensional feature displays. They lack the capability to simultaneously map user-derived differential modification sites onto multi-dimensional contexts, including protein three-dimensional (3D) structure, evolutionary conservation, functional sites, and disease associations. This limitation makes it difficult for researchers to rapidly assess the biological importance of candidate sites from among a vast number of differentially modified sites. Here, we present PTMExplorer, an interactive platform for the multi-dimensional visualization of protein PTMs. PTMExplorer comprises three core modules: PTM Inspector, built upon ProtVista, provides a multi-track, sequence-feature integrated view incorporating intrinsically disordered region (IDR) prediction (via flDPnn), surface accessibility calculation (via FreeSASA), and UniProt functional annotations; PTM 3D Locator, leveraging the Nightingale/Mol* engine, anchors modification sites onto AlphaFold/Protein Data Bank (PDB) 3D structures through residue mapping via PDBe-SIFTS; and PTM Overview, utilizing the R circlize package, presents a panoramic polar circos plot illustrating modification distribution and inter-group differential regulation. Additionally, three major disease-associated modification databases (PTMD, qPTM, and PhosCancer) are integrated as PTM-Disease Nexus, enabling co-localization comparison between user-defined differential sites and reported disease-related sites. PTMExplorer currently supports eight model organisms, accepts user-uploaded differential analysis results, and provides multi-dimensional annotations and various visualization options (https://www.bioladder.cn/PTMExplorer/). Using a multi-omics dataset from hepatocellular carcinoma (18 patients, 9 modification types) as a case study, we demonstrate the practical utility of PTMExplorer in screening potential biomarkers, revealing multi-modification coordination mechanisms, and distinguishing between absolute and relative quantification patterns.

bioinformatics↗

Integrative analysis of the MDM2 promoter switch and cellular lineage plasticity in colorectal cancer: a contrast between the autonomous-proliferation type (CIN/CMS2) and the environment-adaptive type (MSI/gastric metaplasia)

Background: Biomarkers that stratify colorectal cancer (CRC) by therapeutic responsiveness and are measurable directly in biopsy specimens remain insufficiently established. We investigated whether usage of the dual MDM2 promoters (P1/P2) acts as a molecular switch separating two diametrically opposed CRC phenotypes: a chromosomal instability type and an environment adaptive type (microsatellite instability/serrated pathway with gastric metaplasia). Methods: Sixty three organoid samples from 22 patients with CRC were classified morphologically by deep learning (VGG16) and molecularly by an MDM2 Splicing Index derived from expression arrays. The P1 and P2 signatures (gene sets characterizing P1 and P2dominant samples) were externally validated in TCGA-COAD/READ (n = 624) and GSE39582 (n = 536), 1,160 cases in total, and therapeutic implications were tested in public cell line panels (GDSC2, DepMap) and in 65 lines of an independent patient derived CRC organoid biobank. Results: Deep learning morphological classification reached 98.5% test accuracy (64/65), and morphology corresponded to P1/P2 isoform usage: Type1 (compact glandular) morphology predominated in P1 dominant samples (median Type1 fraction 0.826 versus 0.444) and non Type1 (cystic mucinous) morphology in P2 dominant samples (AUC 0.79). Both signatures differed across the four consensus molecular subtypes , and the P2 signature was higher in mismatch repair deficient (microsatellite-unstable) tumors. Promoter usage quantified directly (P2_index) was higher in TP53 wild type tumors , consistent with P2 being p53-inducible. TP53 wild type cell lines were more sensitive to the MDM2 inhibitor Nutlin 3a and were more dependent on MDM2 in the DepMap CRISPR screen ; among 198 GDSC2 drugs, Nutlin 3a correlated most strongly with the P2 score. In the independent biobank, TP53 wild type lines (17) were more sensitive to nutlin-3 than mutant lines (48) (median log(IC50) 1.386 versus 4.283). Conclusions: MDM2 promoter choice (P1/P2) co-varies with the lineage identity of cancer cells and with the secretory, mucin rich character of the tumor tissue, consistent with a molecular-switch role alongside p53 suppression. The MDM2 P1/P2 ratio, measurable by RT qPCR or targeted NGS, is a candidate molecular-classification and therapeutic-stratification biomarker corresponding robustly to CMS, MSI, and TP53 mutation status.

bioinformatics↗